Report cover image

Global Cardiovascular Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 191 Pages
SKU # APRC20278747

Description

Summary

According to APO Research, The global Cardiovascular Disease Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Cardiovascular Disease Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Cardiovascular Disease Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Cardiovascular Disease Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Cardiovascular Disease Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Cardiovascular Disease Drugs include Takeda Pharmaceutical, Sanofi, Johnson&Johnson, Novartis, Merck, Roche, Pfizer, Bayer and AstraZeneca, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Cardiovascular Disease Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Cardiovascular Disease Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Cardiovascular Disease Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cardiovascular Disease Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Cardiovascular Disease Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Cardiovascular Disease Drugs sales, projected growth trends, production technology, application and end-user industry.

Cardiovascular Disease Drugs Segment by Company

Takeda Pharmaceutical
Sanofi
Johnson&Johnson
Novartis
Merck
Roche
Pfizer
Bayer
AstraZeneca
United Therapeutics Corporation
Daiichi Sankyo Company Limited
Boehringer Ingelheim
Astellas Pharma
Actelion Pharmaceuticals
Cardiovascular Disease Drugs Segment by Type

Lotrel
Zebeta
Coumadin
Sectral
Heparin
Lopressor
Norvasc
Toprol XL
Others
Cardiovascular Disease Drugs Segment by Application

Stroke
Dyslipidemia
Thrombosis
Peripheral Artery Disease
Asischemic Heart Disease
Coronary Artery Diseases
Atherosclerosis
Others
Cardiovascular Disease Drugs Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cardiovascular Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cardiovascular Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cardiovascular Disease Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cardiovascular Disease Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cardiovascular Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cardiovascular Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Cardiovascular Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Cardiovascular Disease Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Cardiovascular Disease Drugs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Cardiovascular Disease Drugs Sales Estimates and Forecasts (2020-2031)
1.5 Global Cardiovascular Disease Drugs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Cardiovascular Disease Drugs Market Dynamics
2.1 Cardiovascular Disease Drugs Industry Trends
2.2 Cardiovascular Disease Drugs Industry Drivers
2.3 Cardiovascular Disease Drugs Industry Opportunities and Challenges
2.4 Cardiovascular Disease Drugs Industry Restraints
3 Cardiovascular Disease Drugs Market by Manufacturers
3.1 Global Cardiovascular Disease Drugs Revenue by Manufacturers (2020-2025)
3.2 Global Cardiovascular Disease Drugs Sales by Manufacturers (2020-2025)
3.3 Global Cardiovascular Disease Drugs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Cardiovascular Disease Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Cardiovascular Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Cardiovascular Disease Drugs Manufacturers, Product Type & Application
3.7 Global Cardiovascular Disease Drugs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Cardiovascular Disease Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Cardiovascular Disease Drugs Players Market Share by Revenue in 2024
3.8.3 2024 Cardiovascular Disease Drugs Tier 1, Tier 2, and Tier 3
4 Cardiovascular Disease Drugs Market by Type
4.1 Cardiovascular Disease Drugs Type Introduction
4.1.1 Lotrel
4.1.2 Zebeta
4.1.3 Coumadin
4.1.4 Sectral
4.1.5 Heparin
4.1.6 Lopressor
4.1.7 Norvasc
4.1.8 Toprol XL
4.1.9 Others
4.2 Global Cardiovascular Disease Drugs Sales by Type
4.2.1 Global Cardiovascular Disease Drugs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Cardiovascular Disease Drugs Sales by Type (2020-2031)
4.2.3 Global Cardiovascular Disease Drugs Sales Market Share by Type (2020-2031)
4.3 Global Cardiovascular Disease Drugs Revenue by Type
4.3.1 Global Cardiovascular Disease Drugs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Cardiovascular Disease Drugs Revenue by Type (2020-2031)
4.3.3 Global Cardiovascular Disease Drugs Revenue Market Share by Type (2020-2031)
5 Cardiovascular Disease Drugs Market by Application
5.1 Cardiovascular Disease Drugs Application Introduction
5.1.1 Stroke
5.1.2 Dyslipidemia
5.1.3 Thrombosis
5.1.4 Peripheral Artery Disease
5.1.5 Asischemic Heart Disease
5.1.6 Coronary Artery Diseases
5.1.7 Atherosclerosis
5.1.8 Others
5.2 Global Cardiovascular Disease Drugs Sales by Application
5.2.1 Global Cardiovascular Disease Drugs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Cardiovascular Disease Drugs Sales by Application (2020-2031)
5.2.3 Global Cardiovascular Disease Drugs Sales Market Share by Application (2020-2031)
5.3 Global Cardiovascular Disease Drugs Revenue by Application
5.3.1 Global Cardiovascular Disease Drugs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Cardiovascular Disease Drugs Revenue by Application (2020-2031)
5.3.3 Global Cardiovascular Disease Drugs Revenue Market Share by Application (2020-2031)
6 Global Cardiovascular Disease Drugs Sales by Region
6.1 Global Cardiovascular Disease Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Cardiovascular Disease Drugs Sales by Region (2020-2031)
6.2.1 Global Cardiovascular Disease Drugs Sales by Region (2020-2025)
6.2.2 Global Cardiovascular Disease Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Cardiovascular Disease Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Cardiovascular Disease Drugs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Cardiovascular Disease Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Cardiovascular Disease Drugs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Cardiovascular Disease Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Cardiovascular Disease Drugs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Cardiovascular Disease Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Cardiovascular Disease Drugs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Cardiovascular Disease Drugs Revenue by Region
7.1 Global Cardiovascular Disease Drugs Revenue by Region
7.1.1 Global Cardiovascular Disease Drugs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Cardiovascular Disease Drugs Revenue by Region (2020-2025)
7.1.3 Global Cardiovascular Disease Drugs Revenue by Region (2026-2031)
7.1.4 Global Cardiovascular Disease Drugs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Cardiovascular Disease Drugs Revenue (2020-2031)
7.2.2 North America Cardiovascular Disease Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Cardiovascular Disease Drugs Revenue (2020-2031)
7.3.2 Europe Cardiovascular Disease Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Cardiovascular Disease Drugs Revenue (2020-2031)
7.4.2 Asia-Pacific Cardiovascular Disease Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Cardiovascular Disease Drugs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Cardiovascular Disease Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Takeda Pharmaceutical
8.1.1 Takeda Pharmaceutical Comapny Information
8.1.2 Takeda Pharmaceutical Business Overview
8.1.3 Takeda Pharmaceutical Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Takeda Pharmaceutical Cardiovascular Disease Drugs Product Portfolio
8.1.5 Takeda Pharmaceutical Recent Developments
8.2 Sanofi
8.2.1 Sanofi Comapny Information
8.2.2 Sanofi Business Overview
8.2.3 Sanofi Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Sanofi Cardiovascular Disease Drugs Product Portfolio
8.2.5 Sanofi Recent Developments
8.3 Johnson&Johnson
8.3.1 Johnson&Johnson Comapny Information
8.3.2 Johnson&Johnson Business Overview
8.3.3 Johnson&Johnson Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Johnson&Johnson Cardiovascular Disease Drugs Product Portfolio
8.3.5 Johnson&Johnson Recent Developments
8.4 Novartis
8.4.1 Novartis Comapny Information
8.4.2 Novartis Business Overview
8.4.3 Novartis Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Novartis Cardiovascular Disease Drugs Product Portfolio
8.4.5 Novartis Recent Developments
8.5 Merck
8.5.1 Merck Comapny Information
8.5.2 Merck Business Overview
8.5.3 Merck Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Merck Cardiovascular Disease Drugs Product Portfolio
8.5.5 Merck Recent Developments
8.6 Roche
8.6.1 Roche Comapny Information
8.6.2 Roche Business Overview
8.6.3 Roche Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Roche Cardiovascular Disease Drugs Product Portfolio
8.6.5 Roche Recent Developments
8.7 Pfizer
8.7.1 Pfizer Comapny Information
8.7.2 Pfizer Business Overview
8.7.3 Pfizer Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Pfizer Cardiovascular Disease Drugs Product Portfolio
8.7.5 Pfizer Recent Developments
8.8 Bayer
8.8.1 Bayer Comapny Information
8.8.2 Bayer Business Overview
8.8.3 Bayer Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Bayer Cardiovascular Disease Drugs Product Portfolio
8.8.5 Bayer Recent Developments
8.9 AstraZeneca
8.9.1 AstraZeneca Comapny Information
8.9.2 AstraZeneca Business Overview
8.9.3 AstraZeneca Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 AstraZeneca Cardiovascular Disease Drugs Product Portfolio
8.9.5 AstraZeneca Recent Developments
8.10 United Therapeutics Corporation
8.10.1 United Therapeutics Corporation Comapny Information
8.10.2 United Therapeutics Corporation Business Overview
8.10.3 United Therapeutics Corporation Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 United Therapeutics Corporation Cardiovascular Disease Drugs Product Portfolio
8.10.5 United Therapeutics Corporation Recent Developments
8.11 Daiichi Sankyo Company Limited
8.11.1 Daiichi Sankyo Company Limited Comapny Information
8.11.2 Daiichi Sankyo Company Limited Business Overview
8.11.3 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product Portfolio
8.11.5 Daiichi Sankyo Company Limited Recent Developments
8.12 Boehringer Ingelheim
8.12.1 Boehringer Ingelheim Comapny Information
8.12.2 Boehringer Ingelheim Business Overview
8.12.3 Boehringer Ingelheim Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Boehringer Ingelheim Cardiovascular Disease Drugs Product Portfolio
8.12.5 Boehringer Ingelheim Recent Developments
8.13 Astellas Pharma
8.13.1 Astellas Pharma Comapny Information
8.13.2 Astellas Pharma Business Overview
8.13.3 Astellas Pharma Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Astellas Pharma Cardiovascular Disease Drugs Product Portfolio
8.13.5 Astellas Pharma Recent Developments
8.14 Actelion Pharmaceuticals
8.14.1 Actelion Pharmaceuticals Comapny Information
8.14.2 Actelion Pharmaceuticals Business Overview
8.14.3 Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 Actelion Pharmaceuticals Cardiovascular Disease Drugs Product Portfolio
8.14.5 Actelion Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Cardiovascular Disease Drugs Value Chain Analysis
9.1.1 Cardiovascular Disease Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Cardiovascular Disease Drugs Production Mode & Process
9.2 Cardiovascular Disease Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Cardiovascular Disease Drugs Distributors
9.2.3 Cardiovascular Disease Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.